Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Was The Pediatric Asthma Treatment Market Worth In 2025, And What Is Its Anticipated Value By 2029?
The pediatric asthma treatment market has experienced substantial growth in recent years. It is anticipated to expand from $11.03 billion in 2024 to $11.65 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.6%. This historical expansion can be attributed to the rising occurrence of childhood asthma, increasing awareness regarding respiratory illnesses in children, a surge in air pollution and environmental allergens, heightened healthcare spending on pediatric services, and asthma awareness campaigns conducted by NGOs and healthcare bodies.
The market for pediatric asthma treatments is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $14.39 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 5.4%. This growth during the projected timeframe stems from factors such as the increasing occurrence of allergic conditions among children, the broadened availability of biologic treatments for severe pediatric asthma, escalating investments in developing pediatric drugs, a greater focus on personalized and precision medicine approaches, and an expanding middle-class demographic with access to private healthcare services. Key developments expected within this forecast period encompass the creation of biologic therapies suitable for children, the advancement of rapid tools for allergen identification, the incorporation of electronic health records, breakthroughs in inhaler formulations, and innovations in asthma immunotherapy.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25868&type=smp
What Are The Top Growth Drivers Impacting The Pediatric Asthma Treatment Market Outlook?
The pediatric asthma treatment market is anticipated to experience growth due to the increasing prevalence of respiratory infections. These infections are defined as conditions resulting from viruses, bacteria, or other harmful agents impacting parts of the respiratory system like the nose, throat, airways, and lungs. The heightened occurrence of these infections is mainly attributed to increased air pollution, since exposure to contaminants like particulate matter and nitrogen dioxide compromises the respiratory system, making individuals more vulnerable to illness. By enhancing airway performance and reducing inflammation, pediatric asthma treatment lessens both how often and how severely respiratory infections occur, thereby decreasing susceptibility to infectious agents. For example, data from June 2024 by the Australian Institute of Health and Welfare, an Australian government body, indicated that in 2023, chronic obstructive pulmonary disease contributed 3.6% of the overall disease burden and accounted for 50% of the total burden from respiratory conditions. Furthermore, in 2022, approximately 638,000 individuals in Australia, representing 2.5% of the population, were affected by chronic obstructive pulmonary disease. Consequently, the expanding prevalence of respiratory infections is a key factor propelling the pediatric asthma treatment market forward.
What Are The Key Segments In The Pediatric Asthma Treatment Market?
The pediatric asthma treatment market covered in this report is segmented –
1) By Type: Long-Term Control Medications, Quick-Relief Medications, Other Types
2) By Drug Class: Inhaled Corticosteroids, Long-Acting Beta Agonists, Leukotriene Modifiers, Antihistamines, Biologics
3) By Route Of Administration: Oral Route, Nasal Route, Injectable Route
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Clinics, Home Care, Other End users
Subsegments:
1) By Long-Term Control Medications: Inhaled Corticosteroids, Leukotriene Modifiers, Long-Acting Beta Agonists, Combination Inhalers, Biologic Therapies
2) By Quick-Relief Medications: Short-Acting Beta Agonists, Anticholinergics, Systemic Corticosteroids
3) By Other Types: Immunotherapy, Methylxanthines, Alternative Therapies
Which Trends Are Impacting The Pediatric Asthma Treatment Market?
Major companies in the pediatric asthma treatment market are concentrating on creating advanced therapies, such as monoclonal antibodies, to address and lessen airway inflammation in children. Monoclonal antibodies are engineered proteins that replicate the immune system’s capacity to combat harmful pathogens by precisely targeting specific cells or substances. For instance, in April 2024, the UK-based pharmaceutical and biotechnology firm, AstraZeneca PLC, obtained approval from the U.S. Food and Drug Administration for FASENRA (benralizumab) to be used as an additional maintenance treatment for children aged 6 to 11 years who have severe asthma with an eosinophilic phenotype. This antibody is designed to decrease asthma exacerbations and enhance symptom management by targeting and removing eosinophils. Fasenra is administered via subcutaneous injection initially every 4 weeks for three doses, followed by once every 8 weeks, with pediatric dosages adjusted according to body weight.
Which Industry Leaders Are Driving Innovation Across The Pediatric Asthma Treatment Market?
Major companies operating in the pediatric asthma treatment market are Pfizer Inc., Merck And Co Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Genentech Inc., Chiesi Farmaceutici S.p.A, Dr. Reddy’s Laboratories Ltd, Cipla Ltd, Lupin Limited, Zydus Lifesciences Ltd., ECU Health.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/pediatric-asthma-treatment-global-market-report
What Are The Regional Market Dynamics Impacting The Pediatric Asthma Treatment Industry?
North America was the largest region in the pediatric asthma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric asthma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Pediatric Asthma Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25868&type=smp
Browse Through More Reports Similar to the Global Pediatric Asthma Treatment Market 2025, By The Business Research Company
Asthma Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report
Anti Asthmatics And Copd Drugs Market 2025
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Anti Asthmatics And Copd Drugs Market 2025
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model